1. Scrip
  2. >>New Products

Discounts Will Be Key Factor In US Uptake Of Samsung's Renflexis

 
• By Jung Won Shin

Samsung Bioepis, which has received its first US biosimilar approval, is now set to compete with compatriot rival firm Celltrion in the US infliximab biosimilar sector, where discounting is being seen as a key factor in the uptake of these products.

Samsung Bioepis
Samsung Bioepis headquarters in Incheon, South Korea

Samsung Bioepis Co. Ltd.'s Renflexis, a biosimilar referencing Johnson & Johnson's Remicade (infliximab), is set to compete with its South Korean rival Celltrion Inc.'s Inflectra in the US market as early as the fourth quarter of this year, and price is likely to become a key factor in the uptake of both tumor necrosis factor inhibitor biosimilars.

The just-granted US FDA approval of Renflexis (infliximab-abda, previously referred to as SB2) came 13 months after a filing with the US regulator, and the product will be marketed and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Atai/Beckley Merger Comes At A Transformative Time For Psychedelics

 
• By Kevin Grogan

All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.

Stock Watch: How GSK’s Nucala Info Drip Helped Share Price

 
• By Andy Smith

The information flow in the months before the approval of GSK’s Nucala in COPD provides an interesting case study, and brings to mind the cautionary tale of Alnylam’s Onpattro.

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By Kevin Grogan

But the French major is still keen on early-stage M&A.

Pipeline Watch: Eight Approvals And Nine Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

More from Scrip

ASCO: Regeneron Looks To Become Bigger Immuno-Oncology Player

 
• By Alaric DeArment

The drugmaker presented oral abstracts at the meeting for Libtayo in adjuvant cutaneous squamous-cell carcinoma and linvoseltamab in multiple myeloma.

ASCO: Lupin Presents Early Data On PRMT5 Inhibitor

 
• By Vibha Ravi

ASCO sees the debut of Lupin’s PRMT5 inhibitor candidate LRNP7457, currently in Phase I studies in India. While no drug with this mechanism of action has been approved anywhere so far, several candidates are in clinical trials.

MetaVia Sees Obesity Opportunities Despite Challenging US Market

 
• By Jung Won Shin

Despite new challenges related to obesity drug insurance coverage in the US, MetaVia's CEO is confident in the company's novel contender, which unlike rival GLP-1 therapies doesn’t require dose titration.